Francesco Massari

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 83

Top Topics

Tyrosine Kinase

Radical Prostatectomy

Top Venues

Future oncology (London, England)

Virchows Archiv : an international journal of pathology

This page only lists publications with an associated author ORCID identifier.

Publications

Elisa Tassinari, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? Expert opinion on drug metabolism & toxicology 20 (1-2) (2024)
Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt
Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nature reviews. Urology 21 (7) (2024)
Elisa Tassinari, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? Expert opinion on drug metabolism & toxicology 20 (1-2) (2024)
Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt
Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nature reviews. Urology (2024)
Elisa Tassinari, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? Expert opinion on drug metabolism & toxicology (2024)
Elisa Tassinari, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? Expert opinion on drug metabolism & toxicology (2024)
Francesco Massari, Matteo Rosellini, Veronica Mollica
Overall survival with adjuvant pembrolizumab in renal cell carcinoma - the shock of the lightning. Nature reviews. Urology (2024)
Luisa Di Sciascio, Agnese Orsatti, Francesca Ambrosi, Eugenia Franchini, Francesco Massari, Veronica Mollica, Federico Mineo Bianchi, Maurizio Colecchia, Antonio De Leo, Andres Martin Acosta, João Lobo, Michelangelo Fiorentino, Costantino Ricci
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel. Virchows Archiv : an international journal of pathology (2024)
Daniele Santini, Haoran Li, Giandomenico Roviello, Se Hoon Park, Enrique Grande, Jakub Kucharz, Umberto Basso, Ondrej Fiala, Fernando Sabino Marques Monteiro, Alexandr Poprach, Sebastiano Buti, Javier Molina-Cerrillo, Martina Catalano, Tomas Buchler, Emmanuel Seront, Jawaher Ansari, Zin W Myint, Marwan Ghosn, Fabio Calabrò, Ray Manneh Kopp, Dipen Bhuva, Maria T Bourlon, Michela Roberto, Mattia Alberto Di Civita, Veronica Mollica, Andrea Marchetti, Andrey Soares, Nicola Battelli, Marco Ricci, Ravindran Kanesvaran, Aristotelis Bamias, Camillo Porta, Francesco Massari, Matteo Santoni
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1). Targeted oncology (2024)
Nicole Conci, Elisa Tassinari, Valentina Tateo, Matteo Rosellini, Andrea Marchetti, Costantino Ricci, Francesco Chessa, Matteo Santoni, Enrique Grande, Veronica Mollica, Francesco Massari
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? Molecular diagnosis & therapy (2023)
Costantino Ricci, Francesca Ambrosi, Alessia Grillini, Francesco Massari, Michelangelo Fiorentino, Maurizio Colecchia, Thomas M Ulbright, Andres Martin Acosta
Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation. Virchows Archiv : an international journal of pathology (2023)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, Sang Joon Shin, Jae Lyun Lee, Niven Mehra, Ray S McDermott, Núria Sala-Gonzalez, Peter C Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yanez, Eric Yi-Hsiu Huang, Stephen D Begbie, Rustem Airatovich Gafanov, Maria De Santis, Eli Rosenbaum, Michael P Kolinsky, Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H Poehlein, Evan Y Yu
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Thais Maloberti, Antonio De Leo, Sara Coluccelli, Viviana Sanza, Elisa Gruppioni, Annalisa Altimari, Stefano Zagnoni, Francesca Giunchi, Francesco Vasuri, Michelangelo Fiorentino, Veronica Mollica, Simona Ferrari, Sara Miccoli, Michela Visani, Daniela Turchetti, Francesco Massari, Giovanni Tallini, Dario de Biase
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1 / BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. International journal of molecular sciences 24 (10) (2023)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Giorgia Di Filippo, Eugenia Franchini, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Maurizio Colecchia, Andres Martin Acosta, Michelangelo Fiorentino
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type. Histopathology (2023)
Costantino Ricci, Francesca Ambrosi, Alessia Grillini, Francesco Massari, Michelangelo Fiorentino, Maurizio Colecchia, Thomas M Ulbright, Andres Martin Acosta
Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation. Virchows Archiv : an international journal of pathology 484 (4) (2023)
Costantino Ricci, Francesca Ambrosi, Alessia Grillini, Francesco Massari, Michelangelo Fiorentino, Maurizio Colecchia, Thomas M Ulbright, Andres Martin Acosta
Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation. Virchows Archiv : an international journal of pathology 484 (4) (2023)
Costantino Ricci, Francesca Ambrosi, Alessia Grillini, Francesco Massari, Michelangelo Fiorentino, Maurizio Colecchia, Thomas M Ulbright, Andres Martin Acosta
Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation. Virchows Archiv : an international journal of pathology 484 (4) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15 (2) (2023)
Giacomo Nuvola, Veronica Mollica, Francesco Massari, Cristina Suárez
The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors. Immunotherapy (2023)
Costantino Ricci, Francesca Ambrosi, Tania Franceschini, Francesca Giunchi, Alessia Grillini, Eugenia Franchini, Marco Grillini, Riccardo Schiavina, Francesco Massari, Veronica Mollica, Valentina Tateo, Federico Mineo Bianchi, Lorenzo Bianchi, Matteo Droghetti, Thais Maloberti, Giovanni Tallini, Maurizio Colecchia, Andres Martin Acosta, João Lobo, Kiril Trpkov, Michelangelo Fiorentino, Dario de Biase
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT. Virchows Archiv : an international journal of pathology (2023)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini, Francesco Massari
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel, Switzerland) 16 (4) (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Giacomo Nuvola, Alessandro Rizzo, Veronica Mollica, Francesco Massari
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem? Immunotherapy 14 (4) (2022)
Elisa Tassinari, Veronica Mollica, Giacomo Nuvola, Andrea Marchetti, Matteo Rosellini, Francesco Massari
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy. Cancer management and research 14 (2022)
Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, Matteo Santoni, Veronica Murianni, Ugo De Giorgi, Giuseppe Procopio, Camillo Porta, Michele Milella, Umberto Basso, Francesco Massari, Maruzzo Marco, Roberto Iacovelli, Nicola Battelli, Luca Carmisciano, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic advances in medical oncology 14 (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Rodolfo Montironi, Francesco Massari
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future oncology (London, England) 18 (6) (2022)
Veronica Mollica, Giacomo Nuvola, Elisa Tassinari, Maria Concetta Nigro, Andrea Marchetti, Matteo Rosellini, Alessandro Rizzo, Constantino Errani, Francesco Massari
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current oncology (Toronto, Ont.) 29 (3) (2022)
Matteo Righini, Veronica Mollica, Alessandro Rizzo, Gaetano La Manna, Francesco Massari
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. Journal of clinical medicine 11 (15) (2022)
Matteo Santoni, Francesco Massari, Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Gennaro Palmiotti, Francesco Massari
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. Journal of clinical medicine 11 (4) (2022)
Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, Veronica Mollica, Ursula Maria Vogl, Laura Marandino, Francesco Massari, Ricardo Pereira Mestre, Elisa Zanardi, Alessio Signori, Sebastiano Buti, Matteo Bauckneht, Silke Gillessen Sommer, Giuseppe Luigi Banna, Giuseppe Fornarini
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers 14 (5) (2022)
Andrea Marchetti, Matteo Rosellini, Giacomo Nuvola, Elisa Tassinari, Veronica Mollica, Alessandro Rizzo, Matteo Santoni, Alessia Cimadamore, Andrea Farolfi, Rodolfo Montironi, Stefano Fanti, Francesco Massari
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming? Cancers 14 (4) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer. Journal of clinical medicine 11 (21) (2022)
Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina-Cerrillo, Zin W Myint, Tomas Buchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers 14 (17) (2022)
Matteo Santoni, Javier Molina-Cerrillo, Zin W Myint, Francesco Massari, Tomas Buchler, Sebastiano Buti, Marc R Matrana, Ugo De Giorgi, Mimma Rizzo, Ignacio Ortego Zabalza, Luca Galli, Paolo Andrea Zucali, Gaetano Aurilio, Lorena Incorvaia, Maria Bassanelli, Giulia Mammone, Alessia Salfi, Luca Isella, Veronica Mollica, Enrique Grande, Camillo Porta, Nicola Battelli
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. Targeted oncology 17 (5) (2022)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis. Immunotherapy 14 (8) (2022)
Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Alessandro Rizzo, Matteo Santoni, Francesco Massari
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature reviews. Urology (2022)
Veronica Mollica, Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Alessia Cimadamore, Marina Scarpelli, Chiara Bonucci, Elisa Andrini, Constantino Errani, Matteo Santoni, Rodolfo Montironi, Francesco Massari
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers 13 (3) (2021)
Maria Massucci, Veronica Mollica, Alessandro Rizzo, Laura Ventrella, Ilaria Maggio, Lisa Manuzzi, Lidia Gatto, Giovanni Brandi, Francesco Massari
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. Medicines (Basel, Switzerland) 8 (1) (2021)
Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Antonio Russo, Angelo Martignetti, Mimma Rizzo, Giacomo Cartenì, Enrique Grande, Marc R Matrana, Simon J Crabb, Nuno Vau, Giulia Sorgentoni, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics (Basel, Switzerland) 11 (1) (2021)
Veronica Mollica, Matteo Santoni, Marc R Matrana, Umberto Basso, Ugo De Giorgi, Alessandro Rizzo, Marco Maruzzo, Andrea Marchetti, Matteo Rosellini, Sara Bleve, Diana Maslov, Karine Tawagi, Ernest Philon, Zoe Blake, Francesco Massari
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Targeted oncology (2021)
Alessia Cimadamore, Liang Cheng, Francesco Massari, Matteo Santoni, Laura Pepi, Carmine Franzese, Marina Scarpelli, Antonio López-Beltran, Andrea Benedetto Galosi, Rodolfo Montironi
Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. International journal of molecular sciences 22 (11) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari
Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. Journal of clinical medicine 10 (22) (2021)
Alessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, Angela Dalia Ricci, Ilaria Maggio, Andrea Marchetti, Matteo Rosellini, Matteo Santoni, Andrea Ardizzoni, Francesco Massari
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. Future oncology (London, England) 17 (20) (2021)
Alessia Cimadamore, Roberta Mazzucchelli, Antonio López-Beltran, Francesco Massari, Matteo Santoni, Marina Scarpelli, Liang Cheng, Rodolfo Montironi
Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers 13 (14) (2021)
Veronica Mollica, Stefano Brocchi, Filippo Gustavo Dall'Olio, Laura Marcolin, Alexandro Paccapelo, Matteo Santoni, Alessandro Rizzo, Rodolfo Montironi, Rita Golfieri, Francesco Massari, Andrea Ardizzoni
Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers 13 (14) (2021)
Antonio López-Beltran, Alessia Cimadamore, Ana Blanca, Francesco Massari, Nuno Vau, Marina Scarpelli, Liang Cheng, Rodolfo Montironi
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers 13 (1) (2021)
Francesco Massari, Alessandro Rizzo, Veronica Mollica, Matteo Santoni
A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? Future oncology (London, England) 17 (15) (2021)
Andrea Marchetti, Matteo Rosellini, Veronica Mollica, Alessandro Rizzo, Elisa Tassinari, Giacomo Nuvola, Alessia Cimadamore, Matteo Santoni, Michelangelo Fiorentino, Rodolfo Montironi, Francesco Massari
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? International journal of molecular sciences 22 (12) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Francesco Massari
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future oncology (London, England) 18 (5) (2021)
Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy 13 (8) (2021)
Tania Franceschini, Francesca Giunchi, Veronica Mollica, Annalisa Altimari, Elisa Capizzi, Mattia Banfi, Riccardo Schiavina, Michelangelo Fiorentino, Francesco Massari
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study. Diagnostics (Basel, Switzerland) 11 (2) (2021)
Umberto Basso, Antonella Facchinetti, Elisabetta Rossi, Maruzzo Marco, Vincenza Conteduca, Michele Aieta, Francesco Massari, Anna Paola Fraccon, Claudia Mucciarini, Teodoro Sava, Matteo Santoni, Cristina Pegoraro, Emilia Durante, Maurizio Nicodemo, Alessandra Perin, Alessandra Bearz, Carlo Gatti, Pasquale Fiduccia, Alberto Diminutto, Carmen Barile, Ugo De Giorgi, Rita Zamarchi, Vittorina Zagonel
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. The oncologist 26 (9) (2021)
Matteo Rosellini, Matteo Santoni, Veronica Mollica, Alessandro Rizzo, Alessia Cimadamore, Marina Scarpelli, Nadia Storti, Nicola Battelli, Rodolfo Montironi, Francesco Massari
Treating Prostate Cancer by Antibody-Drug Conjugates. International journal of molecular sciences 22 (4) (2021)
Veronica Mollica, Andrea Marchetti, Matteo Rosellini, Giacomo Nuvola, Alessandro Rizzo, Matteo Santoni, Alessia Cimadamore, Rodolfo Montironi, Francesco Massari
An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International journal of molecular sciences 22 (24) (2021)
Gaetano Aurilio, Matteo Santoni, Francesco Massari, Alessia Cimadamore, Alessandro Rizzo, Veronica Mollica, Elena Verri, Nicola Battelli, Rodolfo Montironi
Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers 13 (20) (2021)
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Giada Grilli, Alba Greco, Rodolfo Montironi, Andrea Ardizzoni, Francesco Massari
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy 13 (9) (2021)
Vincenzo Di Nunno, Matteo Santoni, Veronica Mollica, Alessandro Conti, Rodolfo Montironi, Nicola Battelli, Andrea Ardizzoni, Francesco Massari
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Clinical drug investigation 40 (3) (2020)
Vincenzo Di Nunno, Veronica Mollica, Matteo Brunelli, Lidia Gatto, Riccardo Schiavina, Michelangelo Fiorentino, Matteo Santoni, Rodolfo Montironi, Anna Caliò, Albino Eccher, Michele Milella, Guido Martignoni, Eugenio Brunocilla, Francesco Massari
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. Molecular diagnosis & therapy 23 (5) (2020)
Alessia Cimadamore, Gaetano Aurilio, Franco Nolé, Francesco Massari, Marina Scarpelli, Matteo Santoni, Antonio López-Beltran, Liang Cheng, Rodolfo Montironi
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells 9 (6) (2020)
Matteo Santoni, Francesco Massari, Gaetano Aurilio, Veronica Mollica, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Franco Nolé, Rodolfo Montironi
Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy 12 (17) (2020)
Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Francesca Giunchi, Liang Cheng, Antonio López-Beltran, Michelangelo Fiorentino, Rodolfo Montironi, Francesco Massari
Is There a Role for Immunotherapy in Prostate Cancer? Cells 9 (9) (2020)
Gaetano Aurilio, Alessia Cimadamore, Matteo Santoni, Franco Nolè, Marina Scarpelli, Francesco Massari, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? Cells 9 (6) (2020)
Gaetano Aurilio, Alessia Cimadamore, Roberta Mazzucchelli, Antonio López-Beltran, Elena Verri, Marina Scarpelli, Francesco Massari, Liang Cheng, Matteo Santoni, Rodolfo Montironi
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells 9 (12) (2020)
Francesca Giunchi, Francesco Massari, Annalisa Altimari, Elisa Gruppioni, Elisabetta Nobili, Michelangelo Fiorentino, Andrea Ardizzoni
Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers. Diagnostics (Basel, Switzerland) 10 (12) (2020)
Filippo Gustavo Dall'Olio, Alessandro Rizzo, Veronica Mollica, Maria Massucci, Ilaria Maggio, Francesco Massari
Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 13 (3) (2020)
Veronica Mollica, Alessandro Rizzo, Francesco Massari
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future oncology (London, England) 16 (27) (2020)
Veronica Mollica, Alessandro Rizzo, Rodolfo Montironi, Liang Cheng, Francesca Giunchi, Riccardo Schiavina, Matteo Santoni, Michelangelo Fiorentino, Antonio Lopez-Beltran, Eugenio Brunocilla, Giovanni Brandi, Francesco Massari
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers 12 (6) (2020)
Francesco Massari, Veronica Mollica, Stefania Salvagni, Michele Tognetto, Andrea Ardizzoni
Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care. Future oncology (London, England) 16 (20) (2020)
Francesco Massari, Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi, Giovanni Brandi
The Human Microbiota and Prostate Cancer: Friend or Foe? Cancers 11 (4) (2019)
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi, Francesco Massari
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers 11 (6) (2019)
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Camillio Porta, Marc R Matrana, Giacomo Cartenì, Simon J Crabb, Ugo De Giorgi, Umberto Basso, Cristina Masini, Fabio Calabrò, Maria Giuseppa Vitale, Daniele Santini, Francesco Massari, Luca Galli, Giuseppe Fornarini, Riccardo Ricotta, Sebastiano Buti, Paolo Andrea Zucali, Orazio Caffo, Franco Morelli, Francesco Carrozza, Angelo Martignetti, Alain Gelibter, Roberto Iacovelli, Alessandra Mosca, Francesco Atzori, Nuno Vau, Lorena Incorvaia, Cinzia Ortega, Marina Scarpelli, Antonio López-Beltran, Liang Cheng, Vittorio Paolucci, Jeffrey Graham, Erin Pierce, Sarah Scagliarini, Pierangela Sepe, Elena Verzoni, Sara Merler, Mimma Rizzo, Giulia Sorgentoni, Alessandro Conti, Francesco Piva, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers 12 (1) (2019)
Alessia Cimadamore, Silvia Gasparrini, Francesco Massari, Matteo Santoni, Liang Cheng, Antonio López-Beltran, Marina Scarpelli, Rodolfo Montironi
Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers 11 (2) (2019)
Francesco Massari, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Riccardo Schiavina, Laura Cosmai, Eugenio Brunocilla, Andrea Ardizzoni, Camillo Porta
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Targeted oncology 13 (6) (2019)
Matteo Santoni, Alessia Cimadamore, Francesco Massari, Francesco Piva, Gaetano Aurilio, Angelo Martignetti, Marina Scarpelli, Vincenzo Di Nunno, Lidia Gatto, Nicola Battelli, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi
Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers 11 (9) (2019)